Gosset Year Founded
2012
Ownership
Private
Employees
~50
Therapeutic Areas
Stage
Phase 2
Modalities
IXALTIS General Information
Completed Phase 2 studies for Litoxetine with positive results in 2019. Successful completion of Scientific Advice and End-of-Phase 2 interactions with EMA and FDA in 2020.
Drug Pipeline
litoxetine
Phase 2Key Partnerships
Sanofi
IXALTIS Funding
| Deal Type | Date | Amount | Status | Stage |
|---|
To view IXALTIS's complete valuation and funding history, request access »
IXALTIS Investors
None specifically named, but raised $8.9 million in Series A funding
Investor Type: Venture Capital
Holding: Minority